SCHEMBL6703286

SCHEMBL6703286

O=C(C=Cc1ccc(F)cc1)c1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 1.00
MAOA P21397 5/20 1.00
MAPT P10636 7/20 0.76
MAPK1 P28482 3/20 0.76
KMT2A Q03164 3/20 0.76
ALDH1A1 P00352 2/20 0.76
TP53 P04637 2/20 0.76
KDM4E B2RXH2 2/20 0.76
MEN1 O00255 2/20 0.76
TDP1 Q9NUW8 2/20 0.76
CYP3A4 P08684 1/20 0.76
HPGD P15428 1/20 0.76
ALOX15 P16050 1/20 0.76
ALOX12 P18054 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
CYP2C19 P33261 2/20 0.75
BCHE P06276 2/20 0.75
LMNA P02545 1/20 0.69
NPSR1 Q6W5P4 2/20 0.67
GAA P10253 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25212806 1.00 MAOB (1.00) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL17220893 1.00 MAOB (1.00) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL30382941 1.00 MAOB (1.00) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL30383250 1.00 MAOB (1.00) MAOBMAOAMAPTMAPK1KMT2A
Hydrochloric Acid SCHEMBL25190644 0.98 MAOB (0.97) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL25233412 0.91 MAOB (0.89) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL25191373 0.91 MAOB (0.89) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL25219836 0.91 MAOB (0.89) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL25195966 0.91 MAOB (0.89) MAOBMAOAMAPTMAPK1KMT2A
SCHEMBL25199026 0.86 MAPT (1.00) MAOBMAOAMAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-10308624-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2019-06-04 US disclosed
US-20180099943-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds NORTHWESTERN UNIVERSITY 2018-04-12 US disclosed
US-9840487-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2017-12-12 US disclosed
US-20170217919-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds NORTHWESTERN UNIVERSITY 2017-08-03 US disclosed
US-9624190-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2017-04-18 US disclosed
US-9309217-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2016-04-12 US disclosed
US-20150315168-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same ADVANCED LIFE SCIENCES, INC. 2004-07-29 US disclosed
US-6677350-B1 ADMINISTERING CHALCONE-LIKE VINYLCARBONYL COMPOUNDS TO PREVENT OR TREAT MYCOBACTERIUM INFECTIONS/TUBERCULOSIS ADVANCED LIFE SCIENCES, INC. 2004-01-13 US disclosed
EP-1217995-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME Advanced Life Sciences Inc. (US) 2002-07-03 EP disclosed
WO-2001021164-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME ADVANCED LIFE SCIENCES, INC. (US) 2001-03-29 WO disclosed
US-4571409-A ANTIARRHYTHMIA AGENTS BASF AKTIENGESELLSCHAFT (DE) 1986-02-18 US disclosed
EP-0075207-B1 AMINOPROPANOL DERIVATIVES OF 2-HYDROXY-BETA-PHENYL PROPIOPHENONES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THEM BASF Aktiengesellschaft (DE) 1986-02-05 EP disclosed
US-4540697-A ANTIARRHYTHMIA AGENTS BASF AKTIENGESELLSCHAFT (DE) 1985-09-10 US disclosed
EP-0075207-A2 Aminopropanol derivatives of 2-hydroxy-beta-phenyl propiophenones, processes for their preparation and therapeutic agents containing them BASF Aktiengesellschaft (DE) 1983-03-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217919-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885MAPT 4141/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAOB 1004/4885MAOA 1902/4885MAPT 3297/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAOB 2435/4885MAOA 3145/4885MAPT 3512/4885
US-10308624-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885MAPT 4141/4885
US-20150315168-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885MAPT 4141/4885
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same IMMT, CYP51A1, LSS MAOB 1715/4885MAOA 1739/4885MAPT 2468/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAOB 2435/4885MAOA 3145/4885MAPT 3512/4885
US-20180099943-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885MAPT 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.